Drugs / L-ascorbic acid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00329498 | May 1998 → Aug 2005 | acute myeloid leukemia, myelodysplastic syndrome | Samsung Medical Center | Suspended | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07513727 | Jul 2025 → May 2026 overdue | gingival disorder, hyperpigmentation of the skin | Al-Azhar University | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT04357782 Comparator | Apr → Oct 2020 | COVID-19 | Hunter Holmes Mcguire Veteran Affairs Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03522922 Comparator | Jun 2016 → Feb 2018 | acne | Sohag University | Completed | No outcome recorded |
| Phase 2 | NCT04344184 Comparator | Dec 2020 → Jun 2022 | COVID-19, acute lung injury | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 4 | NCT02355197 Comparator | Jan 2013 → Feb 2015 | gestational diabetes | Cairo University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Ascorbic Acid | “The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum.” NCT03522922 ↗5“Topical application of L-Ascorbic Acid gel (1000 mg in 5 ml distilled water with CMC and PEG), applied once daily on gingival hyperpigmented areas for 1 month.” NCT07513727 ↗ |
| Known as | LAA | “L-ascorbic acid (LAA) modifies the in vitro growth of leukemic cells from approximately 50% of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).” PMID 19284416 ↗ Mar 2009 |
| Known as | vitamin C | “1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery” NCT02355197 ↗ |
| Route | Oral | “subsequent oral LAA supplementation” NCT00329498 ↗ |